Physician profile
Mark J Schultz
NPI 1265477517
$11,024.44
in general payments reported to CMS, 2019-2025
45 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,574 · 2020: $1,695 · 2021: $2,298 · 2022: $1,524 · 2023: $2,273 · 2024: $661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,933.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,933.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,098.27 | 2019-2024 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,067.52 | 2019-2024 | |
| Lilly USA, LLC | $1,005.73 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Glaxosmithkline, LLC. | $920.01 | 2019-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $847.79 | 2019-2023 | Jardiance |
| Novo Nordisk INC | $696.43 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Takeda Pharmaceuticals U.S.A., INC. | $659.19 | 2019-2024 | Trintellix |
| Amgen INC. | $571.55 | 2019-2024 | Repatha, Otezla, Evenity |
| Abbvie INC. | $562.03 | 2021-2023 | Vraylar, Ubrelvy, Qulipta |
| Otsuka America Pharmaceutical, INC. | $368.68 | 2019-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $355.49 | 2019-2024 | Xifaxan |
| Allergan, INC. | $343.63 | 2019-2020 | |
| Abbott Laboratories | $340.12 | 2021-2024 | Freestyle Libre |
| Janssen Pharmaceuticals, INC | $292.62 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $222.19 | 2021 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $212.73 | 2019-2024 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $177.58 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $140.85 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $133.33 | 2019-2024 | Gardasil 9, Vaxelis, Gardasil |
| Dexcom, INC. | $131.87 | 2022-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $100.24 | 2022-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $90.78 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $75.82 | 2019 | |
| Idorsia Pharmaceuticals US INC | $71.16 | 2022-2023 | Quviviq |
| Bayer Healthcare Pharmaceuticals INC. | $58.61 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $52.22 | 2020-2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $50.42 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $37.82 | 2019-2021 | |
| Boston Scientific Corporation | $35.73 | 2023-2024 | Wavewriter Alpha Prime 16, Watchman Access System |
| Dynavax Technologies Corporation | $33.03 | 2022 | |
| Antares Pharma, INC. | $27.97 | 2019-2021 | |
| Mylan Specialty L.P. | $27.02 | 2023-2024 | Yupelri |
| Eisai INC. | $24.89 | 2020 | |
| Xeris Pharmaceuticals, INC. | $23.24 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $20.46 | 2021 | |
| Circassia INC. | $18.22 | 2019 | |
| Edwards Lifesciences Corporation | $17.02 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.63 | 2019 | |
| Corium, LLC | $16.53 | 2023 | Adlarity |
| Shield Therapeutics INC | $16.46 | 2023 | Accrufer |
| Exact Sciences Corporation | $13.96 | 2023 | Cologuard Collection Kit |
| Insulet Corporation | $13.77 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $12.60 | 2022 | |
| Endo Pharmaceuticals INC. | $11.28 | 2021 | |
| Athena Bioscience, LLC | $10.95 | 2023-2024 | Qdolo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.